Volume Alert - PFE 30.20 Pfizer Inc $PFE Hit a high today of 30.28 Closing the day 11/10/14 at 30.20 +0.28 +0.94% With a day low of 29.81 and a total volume of 22,841,941.
PFE Recent Posts: http://investorshangout.com/Pfizer-PFE-52267/
PFE Pfizer Inc Recent Headline News
Most active New York Stock Exchange-traded stocks
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
F: 14.00 (-0.17), ABX.TO: 12.90 (-0.89), ABX: 11.35 (-0.81), S: 4.88 (+0.16), PFE: 30.20 (+0.28), BAC: 17.37 (+0.01), TWTR: 39.59 (-0.72), VZ: 50.72 (-0.14), GNW: 8.12 (-0.29)
Final Glance: Pharmaceuticals companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.82 (+0.62), BAX: 70.63 (+0.02), PFE: 30.20 (+0.28), BMY: 58.81 (+0.49)
Dulled Dow Dogs Dodge Downsides In November
Fredrik Arnold - at Seeking Alpha - Mon Nov 10, 4:38PM CST
KO: 42.39 (+0.07), GE: 26.47 (+0.06), UTX: 109.00 (-0.08), PFE: 30.20 (+0.28), XOM: 96.28 (-0.31), BA: 124.64 (+0.19), T: 35.12 (+0.21), GS: 191.80 (+1.09), JPM: 61.93 (+0.46), IBM: 163.49 (+1.42), MRK: 58.81 (-0.53), MCD: 95.11 (+0.01), PG: 89.45 (+0.32), CAT: 102.21 (+0.45), CVX: 117.92 (-0.88), VZ: 50.72 (-0.14), CSCO: 25.15 (-0.18)
Will Puma Biotechnology (PBYI) Disappoint this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:40PM CST
Puma Biotechnology (PBYI) is expected to report third-quarter 2014 results before the opening bell on Nov 11.
MNK: 93.23 (+2.17), DNDN: 0.18 (-0.76), PFE: 30.20 (+0.28), PBYI: 244.79 (+7.90)
Midday Glance: Pharmaceuticals companies
AP - Mon Nov 10, 12:28PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.82 (+0.62), BAX: 70.63 (+0.02), PFE: 30.20 (+0.28), BMY: 58.81 (+0.49)
Next Resistance Level for Pfizer (PFE) is $30.31
Comtex SmarTrend(R) - Mon Nov 10, 12:04PM CST
Pfizer (NYSE
FE) has opened bullishly above the pivot of $29.94 today and has reached the first level of resistance at $30.11. Analysts will be watching for a cross of the next upside pivot targets of $30.31 and $30.68.
PFE: 30.20 (+0.28)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.62 (-0.04), CRIS: 1.33 (+0.03), IMMU: 3.72 (+0.11), PCYC: 133.98 (+0.49), ONCY: 0.84 (+0.14), PFE: 30.20 (+0.28), LLY: 68.35 (+1.75), BMY: 58.81 (+0.49), GSK: 45.16 (+0.25), JNJ: 108.82 (+0.62), SNTA: 3.11 (-0.03), NVS: 92.63 (+0.87), XLRN: 32.26 (+2.07), ARRY: 3.84 (-0.04), CELGZ: 3.21 (-0.03), EXEL: 1.79 (+0.05)
Early Glance: Pharmaceuticals companies
AP - Mon Nov 10, 9:28AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.82 (+0.62), BAX: 70.63 (+0.02), PFE: 30.20 (+0.28), BMY: 58.81 (+0.49)
Amy Schulman Joins The Board Of Directors Of Blue Buffalo
PR Newswire - Mon Nov 10, 8:34AM CST
Blue Buffalo, the leading natural pet food company, announced today that Amy Schulman joined its Board of Directors. Ms. Schulman is currently the CEO of Arsia Therapeutics Inc., a Venture Partner at Polaris Ventures, and a Senior Lecturer at the Harvard Business School. Until recently, she was the Executive Vice President and General Counsel of Pfizer Inc., as well as the Business Unit Lead of Pfizer's Consumer Healthcare business.
PFE: 30.20 (+0.28)
3 Healthcare Stocks With Unbeatable Dividends
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 9:42AM CST
Large pharmaceutical companies are often known for their generous dividends. Let's check in on three such income generators -- GlaxoSmithKline , AstraZeneca , and Pfizer -- to see if their businesses can back up their yields. Source:...
PFE: 30.20 (+0.28), AZN: 73.21 (+0.33), GSK: 45.16 (+0.25)
MannKind Is On The Mend
Nicholas Kitonyi - at Seeking Alpha - Fri Nov 07, 6:07PM CST
NVO: 43.30 (-0.39), PFE: 30.20 (+0.28), LLY: 68.35 (+1.75), MNKD: 5.88 (+0.10), SNY: 46.19 (+0.50)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 200.98 (+2.40), PFE: 30.20 (+0.28), MRK: 58.81 (-0.53), AZN: 73.21 (+0.33), TEVA: 58.04 (+0.34), ITCI: 15.74 (+0.48), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), OMER: 17.49 (+0.12)
Tracking Kahn Brothers Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Fri Nov 07, 1:17AM CST
MBI: 10.18 (-0.08), NYCB: 15.96 (+0.05), GNE: 6.69 (-0.15), SEB: 3,600.01 (-44.97), PFE: 30.20 (+0.28), BBRY: 11.09 (+0.56), C: 53.89 (+0.14), STRP: 18.36 (-0.58), PTEN: 21.76 (-0.60), SLM: 9.99 (+0.08), VOXX: 8.48 (-0.31), NTP: 5.56 (+0.13), IDT: 17.63 (+0.37), MRK: 58.81 (-0.53), STL: 13.82 (+0.07), BP: 41.86 (-0.20), NYT: 12.84 (+0.08), ORI: 15.06 (-0.02), HOLX: 26.55 (+0.34), NAVI: 20.20 (-0.01)
Will Pfizer Sweeten Its Bid For AstraZeneca?
at Investor's Business Daily - Thu Nov 06, 5:41PM CST
Now that the allure of tax inversion deals for U.S. companies has been damped down, Wall Street is wondering if Pfizer (PFE) will sweeten its takeover bid for AstraZeneca (AZN). The new rules "almost entirely remove the benefits," AstraZeneca CEO...
AZN: 73.21 (+0.33), PFE: 30.20 (+0.28)
Move Over Federal Reserve, There's a New Central Bank in Town
at The Street - Thu Nov 06, 1:35PM CST
The CNBC "Fast Money" trading panel says the stock market can go higher thanks to lower gasoline prices, improved earnings and the European Central Bank.
WFM: 48.05 (+1.24), TSLA: 241.93 (+1.73), VRX: 127.99 (+1.88), KR: 58.56 (+0.76), UN: 38.85 (+0.32), UTX: 109.00 (-0.08), PFE: 30.20 (+0.28), HAL: 53.63 (-0.23), TAP: 76.65 (-0.53), KORS: 69.15 (-0.80), TLT: 118.65 (-1.10), PEP: 96.97 (+0.17), DFS: 66.34 (+0.31), COH: 33.90 (+0.24), SPY: 203.98 (+0.64), QQQ: 101.96 (+0.36), QCOM: 69.36 (+0.10), DIA: 175.95 (+0.37), COST: 137.69 (-0.02), IWM: 117.29 (+0.58), MSFT: 48.89 (+0.21), CBS: 52.13 (+0.82)
PFE Recent Posts: http://investorshangout.com/Pfizer-PFE-52267/
PFE Pfizer Inc Recent Headline News
Most active New York Stock Exchange-traded stocks
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
F: 14.00 (-0.17), ABX.TO: 12.90 (-0.89), ABX: 11.35 (-0.81), S: 4.88 (+0.16), PFE: 30.20 (+0.28), BAC: 17.37 (+0.01), TWTR: 39.59 (-0.72), VZ: 50.72 (-0.14), GNW: 8.12 (-0.29)
Final Glance: Pharmaceuticals companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.82 (+0.62), BAX: 70.63 (+0.02), PFE: 30.20 (+0.28), BMY: 58.81 (+0.49)
Dulled Dow Dogs Dodge Downsides In November
Fredrik Arnold - at Seeking Alpha - Mon Nov 10, 4:38PM CST
KO: 42.39 (+0.07), GE: 26.47 (+0.06), UTX: 109.00 (-0.08), PFE: 30.20 (+0.28), XOM: 96.28 (-0.31), BA: 124.64 (+0.19), T: 35.12 (+0.21), GS: 191.80 (+1.09), JPM: 61.93 (+0.46), IBM: 163.49 (+1.42), MRK: 58.81 (-0.53), MCD: 95.11 (+0.01), PG: 89.45 (+0.32), CAT: 102.21 (+0.45), CVX: 117.92 (-0.88), VZ: 50.72 (-0.14), CSCO: 25.15 (-0.18)
Will Puma Biotechnology (PBYI) Disappoint this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:40PM CST
Puma Biotechnology (PBYI) is expected to report third-quarter 2014 results before the opening bell on Nov 11.
MNK: 93.23 (+2.17), DNDN: 0.18 (-0.76), PFE: 30.20 (+0.28), PBYI: 244.79 (+7.90)
Midday Glance: Pharmaceuticals companies
AP - Mon Nov 10, 12:28PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.82 (+0.62), BAX: 70.63 (+0.02), PFE: 30.20 (+0.28), BMY: 58.81 (+0.49)
Next Resistance Level for Pfizer (PFE) is $30.31
Comtex SmarTrend(R) - Mon Nov 10, 12:04PM CST
Pfizer (NYSE
FE) has opened bullishly above the pivot of $29.94 today and has reached the first level of resistance at $30.11. Analysts will be watching for a cross of the next upside pivot targets of $30.31 and $30.68. PFE: 30.20 (+0.28)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.62 (-0.04), CRIS: 1.33 (+0.03), IMMU: 3.72 (+0.11), PCYC: 133.98 (+0.49), ONCY: 0.84 (+0.14), PFE: 30.20 (+0.28), LLY: 68.35 (+1.75), BMY: 58.81 (+0.49), GSK: 45.16 (+0.25), JNJ: 108.82 (+0.62), SNTA: 3.11 (-0.03), NVS: 92.63 (+0.87), XLRN: 32.26 (+2.07), ARRY: 3.84 (-0.04), CELGZ: 3.21 (-0.03), EXEL: 1.79 (+0.05)
Early Glance: Pharmaceuticals companies
AP - Mon Nov 10, 9:28AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.82 (+0.62), BAX: 70.63 (+0.02), PFE: 30.20 (+0.28), BMY: 58.81 (+0.49)
Amy Schulman Joins The Board Of Directors Of Blue Buffalo
PR Newswire - Mon Nov 10, 8:34AM CST
Blue Buffalo, the leading natural pet food company, announced today that Amy Schulman joined its Board of Directors. Ms. Schulman is currently the CEO of Arsia Therapeutics Inc., a Venture Partner at Polaris Ventures, and a Senior Lecturer at the Harvard Business School. Until recently, she was the Executive Vice President and General Counsel of Pfizer Inc., as well as the Business Unit Lead of Pfizer's Consumer Healthcare business.
PFE: 30.20 (+0.28)
3 Healthcare Stocks With Unbeatable Dividends
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 9:42AM CST
Large pharmaceutical companies are often known for their generous dividends. Let's check in on three such income generators -- GlaxoSmithKline , AstraZeneca , and Pfizer -- to see if their businesses can back up their yields. Source:...
PFE: 30.20 (+0.28), AZN: 73.21 (+0.33), GSK: 45.16 (+0.25)
MannKind Is On The Mend
Nicholas Kitonyi - at Seeking Alpha - Fri Nov 07, 6:07PM CST
NVO: 43.30 (-0.39), PFE: 30.20 (+0.28), LLY: 68.35 (+1.75), MNKD: 5.88 (+0.10), SNY: 46.19 (+0.50)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 200.98 (+2.40), PFE: 30.20 (+0.28), MRK: 58.81 (-0.53), AZN: 73.21 (+0.33), TEVA: 58.04 (+0.34), ITCI: 15.74 (+0.48), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), OMER: 17.49 (+0.12)
Tracking Kahn Brothers Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Fri Nov 07, 1:17AM CST
MBI: 10.18 (-0.08), NYCB: 15.96 (+0.05), GNE: 6.69 (-0.15), SEB: 3,600.01 (-44.97), PFE: 30.20 (+0.28), BBRY: 11.09 (+0.56), C: 53.89 (+0.14), STRP: 18.36 (-0.58), PTEN: 21.76 (-0.60), SLM: 9.99 (+0.08), VOXX: 8.48 (-0.31), NTP: 5.56 (+0.13), IDT: 17.63 (+0.37), MRK: 58.81 (-0.53), STL: 13.82 (+0.07), BP: 41.86 (-0.20), NYT: 12.84 (+0.08), ORI: 15.06 (-0.02), HOLX: 26.55 (+0.34), NAVI: 20.20 (-0.01)
Will Pfizer Sweeten Its Bid For AstraZeneca?
at Investor's Business Daily - Thu Nov 06, 5:41PM CST
Now that the allure of tax inversion deals for U.S. companies has been damped down, Wall Street is wondering if Pfizer (PFE) will sweeten its takeover bid for AstraZeneca (AZN). The new rules "almost entirely remove the benefits," AstraZeneca CEO...
AZN: 73.21 (+0.33), PFE: 30.20 (+0.28)
Move Over Federal Reserve, There's a New Central Bank in Town
at The Street - Thu Nov 06, 1:35PM CST
The CNBC "Fast Money" trading panel says the stock market can go higher thanks to lower gasoline prices, improved earnings and the European Central Bank.
WFM: 48.05 (+1.24), TSLA: 241.93 (+1.73), VRX: 127.99 (+1.88), KR: 58.56 (+0.76), UN: 38.85 (+0.32), UTX: 109.00 (-0.08), PFE: 30.20 (+0.28), HAL: 53.63 (-0.23), TAP: 76.65 (-0.53), KORS: 69.15 (-0.80), TLT: 118.65 (-1.10), PEP: 96.97 (+0.17), DFS: 66.34 (+0.31), COH: 33.90 (+0.24), SPY: 203.98 (+0.64), QQQ: 101.96 (+0.36), QCOM: 69.36 (+0.10), DIA: 175.95 (+0.37), COST: 137.69 (-0.02), IWM: 117.29 (+0.58), MSFT: 48.89 (+0.21), CBS: 52.13 (+0.82)
